MYND forms diagnostic subsidiary to market tests for psychiatric disorders
MYND Diagnostics will carry out trials to detect a marker for diagnosing and monitoring depression in response to treatment.

MYND Diagnostics will carry out trials to detect a marker for diagnosing and monitoring depression in response to treatment.
Infrascanner uses near-infrared spectroscopy to detect intracranial hematomas based on differential light absorption.
Ransomware attacks in the medical industry are compromising patient safety and care and have contributed to increased mortality rates.
ByThe proportion of preterm infants with appropriate PaCO₂ was higher in the EMMA arm compared to the control.
The clearance will enable NeuroOne to market Evo sEEG Electrode for uses of less than 24 hours.
Persona IQ offers objective data to monitor post-operative progress in total knee replacement surgery patients.
Data adjusted for the Covid-19 impact showed that the device led to a significant decrease in heart failure hospitalisations.
The portable MRI system is cheaper compared to conventional MRI technologies and requires minimal training for usage.
Thank you for subscribing to Medical Device Network